Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-α soluble receptor in uveitis C. Bloquel * , R. Bejjani † , P. Bigey * , F. Bedioui * , M. Doat † , D. BenEzra † ,‡ , D. Scherman * ,1 and F. Behar-Cohen † ,§ * INSERM, U640, CNRS, UMR8151, René Descartes Paris 5 University, Faculté des Sciences Pharmaceutiques et Biologiques, Chemical and Genetic Pharmacology Laboratory, Ecole Nationale Supérieure de Chimie de Paris, Paris, France; † INSERM, U598, René Descartes Paris 5 University, Physiopathology of Ocular Diseases: Therapeutic Implications, Paris, France; ‡ Hadassah Hebrew University Hospital, Jerusalem, Israel; and § Laboratoire d’Innovations Thérapeutiques, Rothschild Foundation, Paris, France 1 Correspondence: Chemical and Genetic Pharmacology Laboratory, INSERM U640, CNRS UMR8151, René Descartes University, 4 avenue de l’Observatoire, Paris 75270, France. E-mail: daniel.scherman@univ-paris5.fr <h3>SPECIFIC AIMS</h3> Development of specific ocular drug delivery systems is currently a major research avenue in ophthalmology. Due to the existing ocular barriers, systemic drug administration requires high drug concentrations, enhancing the potential for secondary complications. On the other hand, because of its relatively small size and its particular isolating characteristics, the eye is an ideal target for development of local delivery therapeutic
/lp/fed-of-american-socs-for-experimental-biology/plasmid-electrotransfer-of-eye-ciliary-muscle-principles-and-dObs0hoj0k